Abstract
Aims Advanced nonmalignant respiratory diseases are associated with significant patient morbidity, yet access to palliative care occurs late, if at all. Our aim was to examine referral criteria for palliative care among patients with advanced nonmalignant respiratory disease, with a view to developing a standardised set of referral criteria.
Methods We performed a systematic review of all studies reporting on referral criteria to palliative care in advanced nonmalignant respiratory disease, with a focus on chronic obstructive pulmonary disease and interstitial lung disease. The systematic review was conducted and reported according to the PRISMA guidelines, and was undertaken using electronic databases (Ovid, MEDLINE, Ovid Embase and PubMed).
Results Searches yielded 2052 unique titles, which were screened for eligibility and resulted in 62 studies addressing referral criteria to palliative care in advanced nonmalignant respiratory disease. Of 18 categories put forward for referral to palliative care, the most commonly discussed factors were hospital use (69% of papers), indicators of poor respiratory status (47%), physical and emotional symptoms (37%), functional decline (29%), need for advanced respiratory therapies (27%), and disease progression (26%).
Conclusion Clinicians consider referral to specialist palliative care for a wide range of disease- and needs-based criteria. Our findings highlight the need to standardise palliative care access by developing consensus referral criteria for patients with advanced nonmalignant respiratory illnesses.
Abstract
This systematic review reveals there are multiple different criteria currently used to prompt referral to palliative care, suggesting a lack of consensus around this practice and highlighting the need to establish agreed criteria going forward https://bit.ly/38H7W3i
Footnotes
This article has supplementary material available from erj.ersjournals.com
Conflict of interest: J. Philip has nothing to disclose.
Conflict of interest: A. Collins has nothing to disclose.
Conflict of interest: N. Smallwood has nothing to disclose.
Conflict of interest: Y.K. Chang has nothing to disclose.
Conflict of interest: L. Mo has nothing to disclose.
Conflict of interest: I.A. Yang has nothing to disclose.
Conflict of interest: T. Corte reports grants from Boehringer Ingelheim, Hoffman-La Roche, Gilead, Biogen, Bayer, Intermune and Actelion, personal fees for consultancy from Boehringer Ingelheim, AstraZeneca, BMS, Promedior and Ad Alta, outside the submitted work.
Conflict of interest: C.F. McDonald reports other (fees for lectures paid to institution) from Menarini and AstraZeneca, nonfinancial support (in kind support for research) from Air Liquide, outside the submitted work.
Conflict of interest: D. Hui has nothing to disclose.
- Received November 24, 2020.
- Accepted March 6, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org